MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is expanding its AI-driven voice analytics platform to include a fatigue detection module, aiming to enhance safety in high-risk workplace environments. The company announced on May 11 that it has developed a fatigue recognition system using speech analytics and proprietary artificial intelligence models, according to a news release (https://ibn.fm/4KNzG).
The fatigue prediction capability will be added to MindBio's planned Edge AI Intoxication Detection Kiosks, which are designed to identify signs of drug and alcohol impairment. This expansion positions the company's technology as a non-invasive alternative to traditional breath, saliva, blood, and laboratory-based testing systems. The kiosks are targeted at industrial workplaces, with mining, aviation, transportation, and construction among the initial sectors for deployment.
MindBio has filed a patent application covering the detection of neurologically active substances and fatigue through voice analysis. The company's management confirmed that commercial testing of the kiosk hardware and software remains on track for late Q2 2026. This development underscores the growing interest in AI-based safety tools that can provide real-time, non-invasive monitoring of workers' cognitive states.
The implications of this announcement are significant for industries where operator fatigue and impairment are leading causes of accidents. By integrating both intoxication and fatigue detection into a single platform, MindBio offers a comprehensive solution that could reduce workplace incidents and improve overall safety. The use of voice analytics eliminates the need for biological samples, potentially simplifying compliance and reducing costs for employers.
For investors, the expansion of the platform could open new market opportunities and differentiate MindBio from competitors focused solely on drug and alcohol testing. The company's progress toward commercial testing in late Q2 2026 suggests a clear roadmap to market entry, though the timeline remains subject to development and regulatory milestones.
The latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF. As the technology moves toward commercial deployment, stakeholders in high-risk industries will be watching closely for pilot results and broader adoption.
